Gastric Cancer Subtype May Affect Bevacizumab Benefit

Health News Daily Jan. 27, 2012
Word Count: 746 / Article # 29120127002

Executive Summary

New analysis shows one-third reduction in risk of death for patients with diffuse or distal gastric cancer.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 746-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

+ Show All | – Hide All

There are no current related articles

Offers & Events

Topics Covered in this Article

Click a keyword for related articles.
Subjects
Clinical Development & Trials
Industries
Biopharmaceuticals
Therapeutic Categories
Cancer
Gastrointestinal Cancer
Regions
Europe
North America
United States
Companies
Memorial Sloan-Kettering Cancer Center
Roche
Genentech Inc.
Bayer AG
Sanofi

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Gastric Cancer Subtype May Affect Bevacizumab Benefit

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Health News Daily will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel